Zacks Research Analysts Reduce Earnings Estimates for Bruker

Bruker Co. (NASDAQ:BRKR - Free Report) - Equities researchers at Zacks Research reduced their Q3 2025 earnings per share estimates for shares of Bruker in a research note issued on Tuesday, November 26th. Zacks Research analyst R. Department now expects that the medical research company will earn $0.72 per share for the quarter, down from their prior forecast of $0.94. The consensus estimate for Bruker's current full-year earnings is $2.40 per share. Zacks Research also issued estimates for Bruker's Q4 2025 earnings at $0.96 EPS.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing analysts' consensus estimates of $0.61 by ($0.01). Bruker had a net margin of 9.41% and a return on equity of 21.52%. The business had revenue of $864.40 million during the quarter, compared to analyst estimates of $866.46 million. During the same period in the prior year, the business posted $0.74 EPS. The company's revenue for the quarter was up 16.4% compared to the same quarter last year.

Several other equities analysts have also issued reports on BRKR. Wells Fargo & Company cut their target price on shares of Bruker from $78.00 to $75.00 and set an "overweight" rating on the stock in a research note on Wednesday, November 6th. TD Cowen decreased their target price on Bruker from $72.00 to $70.00 and set a "hold" rating for the company in a research report on Wednesday, November 6th. Barclays cut their price target on Bruker from $75.00 to $69.00 and set an "overweight" rating on the stock in a report on Wednesday, November 6th. Citigroup decreased their price objective on Bruker from $80.00 to $75.00 and set a "buy" rating for the company in a report on Wednesday, November 6th. Finally, Wolfe Research cut Bruker from an "outperform" rating to a "peer perform" rating in a report on Monday, September 30th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $79.36.

Bruker Price Performance

BRKR stock traded up $0.88 during midday trading on Thursday, reaching $58.38. 1,436,451 shares of the stock were exchanged, compared to its average volume of 1,115,677. The company has a fifty day moving average price of $61.02 and a 200 day moving average price of $64.24. Bruker has a 52 week low of $48.07 and a 52 week high of $94.86. The stock has a market capitalization of $8.85 billion, a PE ratio of 28.07, a P/E/G ratio of 3.95 and a beta of 1.20. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Monday, December 2nd will be issued a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, December 2nd. This represents a $0.20 dividend on an annualized basis and a yield of 0.34%. Bruker's dividend payout ratio (DPR) is currently 9.62%.

Insider Buying and Selling

In other Bruker news, CEO Frank H. Laukien bought 100,000 shares of the business's stock in a transaction on Monday, November 18th. The stock was purchased at an average price of $50.14 per share, for a total transaction of $5,014,000.00. Following the completion of the transaction, the chief executive officer now directly owns 38,439,563 shares of the company's stock, valued at $1,927,359,688.82. This trade represents a 0.26 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. 28.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Bruker

A number of large investors have recently made changes to their positions in BRKR. First Horizon Advisors Inc. boosted its position in shares of Bruker by 120.4% in the second quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company's stock valued at $25,000 after acquiring an additional 218 shares during the period. True Wealth Design LLC lifted its stake in Bruker by 4,636.4% in the 3rd quarter. True Wealth Design LLC now owns 521 shares of the medical research company's stock worth $36,000 after purchasing an additional 510 shares in the last quarter. UMB Bank n.a. boosted its holdings in Bruker by 115.3% in the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company's stock valued at $46,000 after purchasing an additional 354 shares during the period. Gordian Capital Singapore Pte Ltd purchased a new position in shares of Bruker during the 2nd quarter valued at $52,000. Finally, GAMMA Investing LLC grew its position in shares of Bruker by 81.0% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the medical research company's stock valued at $60,000 after purchasing an additional 388 shares in the last quarter. 79.52% of the stock is owned by institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.